Эффективность, безопасность и переносимость генноинженерного биологического препарата инфликсимаба у больных анкилозирующим спондилитом

Автор: Тюрин В.П., Мезенова Татьяна Валентиновна, Давидьян С.Ю., Елонаков А.В.

Журнал: Вестник Национального медико-хирургического центра им. Н.И. Пирогова @vestnik-pirogov-center

Статья в выпуске: 2 т.7, 2012 года.

Бесплатный доступ

Представлены результаты изучения эффективности, безопасности и переносимости инфликсимаба у больных анкилозирующим спондилитом.

Анкилозирующий спондилит, лечение

Короткий адрес: https://sciup.org/140188079

IDR: 140188079

Список литературы Эффективность, безопасность и переносимость генноинженерного биологического препарата инфликсимаба у больных анкилозирующим спондилитом

Russel AS. History. In: Hochberg M, et al., eds. Rheumatology. Section 9: Spondylоarthropathies. Spain: Elsevier 2003; 1145.
Khan MA. Clinical features of ankylosing spondylitis. In: Hochberg M, et al., eds. Rheumatology. Section 9: Spondylоarthropathies. Spain: Elsevier 2003; 1161-1181.
Cruyssen B.V., Ribbens C., Boonen A. et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007; 66: 1072-1077.
Lee W., Reveille J.D., Weisman M.H. Women With Ankylosing spondylitis: A Review. Arthr & Rheum. March 15, 2008; 59: N.3. 449-454.
Brown M, Wordworth В, Reveille J. Genetics of ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 (Suppl. 28): 43-49.
David CS. The mystery of HLA-B27 and disease. Immunogenetics. 1997; 46: 73-77.
Bluestone R. Identification of associations with HLA-B27. Milestones Rheumatol Patient Care 1988; 31: 15-24.
Khan MA. Thoughts concerning the early diagnosis of ankylosing spondylitis and related diseases. Clin Exp Rheumatol 2002; 20: S6-S10.
Vernon-Roberts B, Hochberg М, et al. Ankylosing spondylitis: pathology. Rheumatology. Section 9: Spondylarthropathies. Spain: Elsevier 2003; 1205.
Koehler L, Hochberg M, Kuipers J, et al. Enthesopathy. Rheumatology. Section 9: Spondylarthropathies. Spain: Elsevier 2003; 1275-1281.
Morris R, Metzger A, Bluestone R. HLA B27-a useful discriminator in the arthropathies of inflammatory bowel disease. N Engl J Med 1974; 290: 1117-1119.
Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNFa and IFNa in ankylosing spondylitis: its relation to HLA B27 and influens of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001; 60: 36-42.
Milicic A, Lindheimer F, Laval S, et al. Interethnic studies of the TNF polymorphism confirm the likely presense of a second MHC susceptibility locus in ankylosing spondylitis. Genes Immun 2000; 1: 418-422.
McGarry F, Walker R, Sturrock R, Field M. The-308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA B27. J Rheumatol 1999; 26: 1110-1116.
Hohler T, Schaper T, Schneider PM, Meyer zum Buschenfelde KH, MarkerHermann E. Association of different tumor necrosis factor a promoter allele frequencies with ankylosing spondylitis in HLA B27 positive individuals. Arthritis Rheum. 1998;41:1489-1492.
Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentr trial Lancet. 2002; Vol. 359: 1187-1193.
Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) in spondylarthropathies an open pilot study. Ann Rheum Dis 2000; Vol. 59: 428-433.
Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Therapy 2005; Vol. 7: 439-444.
Baraliakos X, Listing J, Brandt J, et al. Persistent clinical response to the anti TNF-a antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatol. 2005. Vol. 44: 670-676.
Бунчук Н.В., Румянцева О.А., Логинова Е.Ю., и др. Эффективность и безопасность инфликсимаба у больных анкилозирующим спондилитом: результаты открытого многоцентрового исследования. Терапевтический архив 2010; №10: С. 41-46.
Pedersen S.J. Responsiveness of the Ankylosing spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumor necrosis factor a inhibitors/S. J. Pedersen, I.J. Sorensen, O.R. Madsen//Ann Rheum Dis. 2010; 69: 1065-1071.
Anderson JJ, Baron G, van der Heijde D et al. Ankylosing spondylitis assessment group preliminary definition of shorttrm improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86.
Loreto Carmona, Juan J Gomez-Reino and on behalf of the BIOBADASER Group Survival of TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis Data from the Spanish registry BIOBADASER Arthritis Research & Therapi. 2006; R:72 () DOI: 10.1186/ar1941
Breban M. Efficacy of infliximab in refractori ankylosing spondylitis results of a six-month open-label stady. Rheumatology 2002; 41: 1280-1285.
Schiff M, Keiserman M, Codding С, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096-1103.

Еще

Статья научная